Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hampig R Kourie

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Future Oncology (London, England)|August 18, 2020
Targeting HER2 in the management of potentially resectable gastric adenocarcinoma: what are oncologists waiting for?Khalil El Gharib, Hampig R Kourie
Epigenomics|April 7, 2021
<i>NTRK</i> genes and cancer: when arresting the fusion underlies the treatmentKhalil El Gharib, Hampig R Kourie
Current Opinion in Oncology|May 3, 2016
Side-effects of checkpoint inhibitor-based combination therapyHampig R Kourie, Jean A Klastersky
Current Opinion in Oncology|December 28, 2016
Concurrent driver mutations/rearrangements in non-small-cell lung cancerSamer Tabchi, Hampig R Kourie, Jean Klastersky
Future Oncology (London, England)|September 15, 2016
Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectivesFady G Haddad, Hampig R Kourie, Joseph Kattan
Discovery Medicine|September 1, 2015
Novel mechanisms and approaches in the medical therapy of solid cancersGil Awada, Hampig R Kourie, Ahmad H Awada
Current Opinion in Oncology|May 7, 2016
Rare side-effects of checkpoint inhibitorsHampig R Kourie, Gil Awada, Ahmad H Awada
Immunotherapy|December 22, 2016
Dermatologic adverse events of checkpoint inhibitors: what an oncologist should knowMaya Habre, Samer Bassilios Habre, Hampig R Kourie
Biomarkers in Medicine|February 24, 2021
Predictive biomarkers in bladder cancerMarwan Alkassis, Hampig R Kourie, Julien Sarkis, et al.
Le Journal Medical Libanais. the Lebanese Medical Journal|November 20, 2018
EARLY INCREASE of CA 19-9 in ADVANCED PANCREATIC CANCER RECEIVING FOLFIRINOX. Is it a sign of efficacy?Samer Tabchi, Hampig R Kourie, Fadi Farhat, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Future Oncology (London, England)|August 18, 2020
Targeting HER2 in the management of potentially resectable gastric adenocarcinoma: what are oncologists waiting for?Khalil El Gharib, Hampig R Kourie
Epigenomics|April 7, 2021
<i>NTRK</i> genes and cancer: when arresting the fusion underlies the treatmentKhalil El Gharib, Hampig R Kourie
Current Opinion in Oncology|May 3, 2016
Side-effects of checkpoint inhibitor-based combination therapyHampig R Kourie, Jean A Klastersky
Current Opinion in Oncology|December 28, 2016
Concurrent driver mutations/rearrangements in non-small-cell lung cancerSamer Tabchi, Hampig R Kourie, Jean Klastersky
Future Oncology (London, England)|September 15, 2016
Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectivesFady G Haddad, Hampig R Kourie, Joseph Kattan
Discovery Medicine|September 1, 2015
Novel mechanisms and approaches in the medical therapy of solid cancersGil Awada, Hampig R Kourie, Ahmad H Awada
Current Opinion in Oncology|May 7, 2016
Rare side-effects of checkpoint inhibitorsHampig R Kourie, Gil Awada, Ahmad H Awada
Immunotherapy|December 22, 2016
Dermatologic adverse events of checkpoint inhibitors: what an oncologist should knowMaya Habre, Samer Bassilios Habre, Hampig R Kourie
Biomarkers in Medicine|February 24, 2021
Predictive biomarkers in bladder cancerMarwan Alkassis, Hampig R Kourie, Julien Sarkis, et al.
Le Journal Medical Libanais. the Lebanese Medical Journal|November 20, 2018
EARLY INCREASE of CA 19-9 in ADVANCED PANCREATIC CANCER RECEIVING FOLFIRINOX. Is it a sign of efficacy?Samer Tabchi, Hampig R Kourie, Fadi Farhat, et al.
Pageof 3